Antibody Specificity Profiling
Research and development of protein arrays and their applications in proteomics
Cross-reactivity is an often overlooked issue with antibodies, with typical QC involving proof of binding to the intended target, but neglecting broad screens for potential cross-reactivity.
Screening your antibody of HuProt™ v4 arrays enables identification of potential cross-reactivities across the 80% of the human proteome. This is of particularly high value for the characterisation of therapeutic or diagnostic candidate antibodies, where cross-reactivities provide an early indication of possible off-target effects in vivo, or of potentially misleading diagnostic readouts. By eliminating candidate antibodies which show cross-reactivities from the development process, significant savings in cost and time can be achieved.
Analogous to classical antibodies, alternative binder types can also be assayed on HuProt™arrays.
See here for references of HuProt™ applications in binder profiling!
Typically, the antibody of interest is incubated on the HuProt™ array, followed by a suitable fluorophore-labelled secondary reagent. Alternatively, if the antibody of interest is fluorophore-conjugated itself, incubation and detection can proceed in one step.